Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the safety and tolerability of SAGE-718 in participants with Parkinson's disease and mild cognitive impairment (PD-MCI); the trial is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SAGE-718

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Parkinson Disease, Cognitive Dysfunction | Phase 2 | Status: COMPLETED | Results posted: 2023-06-06